Catalyst Biosciences (CBIO) Cut to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Catalyst Biosciences (NASDAQ:CBIO) from a buy rating to a hold rating in a research note published on Monday morning.

According to Zacks, “Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company’s hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif. “

Separately, B. Riley set a $19.00 price objective on shares of Catalyst Biosciences and gave the company a buy rating in a research report on Monday, December 18th.

Catalyst Biosciences (CBIO) opened at $15.07 on Monday. The firm has a market cap of $83.54, a PE ratio of -1.15 and a beta of 1.86. Catalyst Biosciences has a 1 year low of $3.11 and a 1 year high of $18.88.

A number of large investors have recently added to or reduced their stakes in CBIO. Virtu KCG Holdings LLC bought a new position in Catalyst Biosciences during the second quarter worth about $103,000. Bank of New York Mellon Corp bought a new position in Catalyst Biosciences during the second quarter worth about $107,000. Zacks Investment Management bought a new position in Catalyst Biosciences during the second quarter worth about $147,000. Vanguard Group Inc. increased its position in Catalyst Biosciences by 294.1% during the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after acquiring an additional 32,621 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in Catalyst Biosciences during the second quarter worth about $372,000. 28.39% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3126407/catalyst-biosciences-cbio-cut-to-hold-at-zacks-investment-research.html.

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.